Format

Send to

Choose Destination
Kidney Int. 2008 Sep;74(6):695-7. doi: 10.1038/ki.2008.263.

The mortality risk associated with higher hemoglobin: is the therapy to blame?

Author information

1
Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.

Abstract

Recent trials have demonstrated a trend for increased mortality when patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD) are treated with erythropoietin-stimulating agents (ESAs) to hemoglobin levels higher than recommended (>13 g/dl). Recent studies suggest that higher doses of ESAs, in themselves, may be at least partly responsible for this mortality risk. This is important, as more than 90% of patients with ESRD and approximately 20% of patients with CKD receive ESAs. Two new studies address this.

PMID:
18756292
DOI:
10.1038/ki.2008.263
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center